Topics

Search Results for "Desmoglein 2"

23:55 EST 22nd January 2020 | BioPortfolio

Matching Channels

None

Matching News

Matching PubMed Articles

Clinical efficacy of rituximab in the treatment of pemphigus vulgaris: a 10-year follow-up.

We previously published results on six patients, with mucocutaneous Pemphigus vulgaris (PV), treated with rituximab for recalcitrant disease (1). These patients and four others were followed-up for 10...

Desmoglein 3 gene mediates epidermal growth factor/epidermal growth factor receptor signaling pathway involved in inflammatory response and immune function of anaphylactic rhinitis.

To investigate the effects of desmoglein 3 (DSG3) gene mediating epidermal growth factor/epidermal growth factor receptor (EGF/EGFR) signaling pathway on inflammatory response and immune function of a...

Evaluation of the pathogenicity of anti-desmoglein antibodies of pemphigus vulgaris patients using human organ culture assay.

Anti-desmoglein (anti-Dsg) antibodies are key players in the pathogenesis of pemphigus vulgaris (PV) disease. We aimed to evaluate the pathogenicity of anti-Dsg antibodies of PV patients using human o...

The involvement of ADAM10 in mucocutaneous pemphigus vulgaris acantholysis depends on the autoantibody profile in each patient.

Acantholysis in pemphigus vulgaris (PV) may be triggered by desmoglein (Dsg) and non-Dsg autoantibodies. The autoantibody profile of each patient results in distinct intracellular signaling patterns.

A common indel polymorphism of the Desmoglein-2 (DSG2) is associated with sudden cardiac death in Chinese populations.

Sudden cardiac death (SCD) is referred to as sudden and unexpected death caused by cardiovascular diseases, in which a person preexisted heart disease or not. Compelling evidence indicates that SCD et...

Search Whole site using Google

Loading
Quick Search
Advertisement Advertisement